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AbsTrACT
background Most patients with path_MMR gene 
variants (lynch syndrome (lS)) now survive both their 
first and subsequent cancers, resulting in a growing 
number of older patients with lS for whom limited 
information exists with respect to cancer risk and 
survival.
Objective and design this observational, 
international, multicentre study aimed to determine 
prospectively observed incidences of cancers and 
survival in path_MMR carriers up to 75 years of age.
results 3119 patients were followed for a total 
of 24 475 years. cumulative incidences at 75 years 
(risks) for colorectal cancer were 46%, 43% and 
15% in path_MLH1, path_MSH2 and path_MSH6 
carriers; for endometrial cancer 43%, 57% and 
46%; for ovarian cancer 10%, 17% and 13%; for 
upper gastrointestinal (gastric, duodenal, bile duct or 
pancreatic) cancers 21%, 10% and 7%; for urinary 
tract cancers 8%, 25% and 11%; for prostate cancer 
17%, 32% and 18%; and for brain tumours 1%, 5% 
and 1%, respectively. Ovarian cancer occurred mainly 
premenopausally. By contrast, upper gastrointestinal, 
urinary tract and prostate cancers occurred 
predominantly at older ages. Overall 5-year survival 
for prostate cancer was 100%, urinary bladder 93%, 
ureter 85%, duodenum 67%, stomach 61%, bile 
duct 29%, brain 22% and pancreas 0%. Path_PMS2 
carriers had lower risk for cancer.
Conclusion carriers of different path_MMR variants 
exhibit distinct patterns of cancer risk and survival as 
they age. risk estimates for counselling and planning 
of surveillance and treatment should be tailored to 
each patient’s age, gender and path_MMR variant. We 
have updated our open-access website www. lscarisk. 
org to facilitate this.
InTrOduCTIOn
Lynch syndrome (LS) is associated with a high prob-
ability of gastrointestinal, gynaecological and other 
cancers.1 2 It is caused by germline pathogenic vari-
ants in any of four DNA MMR genes referred to 
here as path_MSH2, path_MLH1, path_PMS2 or 
path_MSH6 and collectively as path_MMR. Dele-
tions in the EPCAM gene, which lead to inher-
ited methylation of the adjacent MSH2 promoter, 
are also referred to as path_MSH2. To date, most 
patients with LS have been identified following 
investigation because of their family or personal 
history of multiple and/or early onset cancers.
Carriers of path_MMR variants require reliable 
information about their future cancer risks so that 
they can be offered appropriately targeted surveil-
lance. However, a paucity of prospectively obtained 
information has led current clinical guidelines to 
rely heavily upon retrospective data from patient 
cohorts whose selection for molecular testing has 
been subject to bias. The efficacy of effects of inter-
ventions to prevent cancers in path_MMR carriers 
is debated.1–4
Most patients with LS receiving surveillance for 
LS-associated tumours develop colorectal, gynaeco-
logical or other cancers and now survive both their 
first and subsequent cancers.1 2 The consequence is 
a growing and ageing population of patients with 
LS. There is limited information on their cancer 
risks and survivals. One reason for this is that in 
former generations most patients with LS died from 
their first cancer, and the risks for survivors are 
therefore difficult to determine from retrospective 
family studies.5 A second reason is that measures 
to prevent or cure early onset cancers in LS are 
recent developments that have benefited mainly 
younger patients with LS. A third reason is the 
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possibility that patients with LS affected by cancer at younger 
ages might have path_MMR variants of higher penetrance (as in 
path_BRCA16) and/or carry genetic modifiers that increase pene-
trance7 and/or were exposed to a more carcinogenic environ-
ment (as for path_RB8).
Indeed, it was unknown whether LS patients with and without 
early onset cancer had similar risks for cancer later in life. If 
the risks differed substantially, these groups could not be pooled 
when assessing risks in older patients. The first report from the 
Prospective Lynch Syndrome Database (PLSD) described LS 
patients without cancer before their inclusion and showed that 
the different path_MMR genes had different penetrance and/
or expression.1 Few previous prospective reports had stratified 
results this way and the question of whether LS patients with 
early onset cancer have an increased risk for subsequent cancer 
could be confounded by differences related to which path_MMR 
gene the patients carried. We examined this issue further in a 
second report from PLSD and found similar future cancer inci-
dence in patients with LS who had a previous cancer compared 
with those who did not, when stratifying by path_MMR gene.2 
These findings allowed us to combine the two groups in the 
present report.
No single centre has sufficient patient numbers to estimate 
risks in older individuals and international multicentre collabo-
ration is needed to obtain results within a reasonable timeframe. 
The PLSD provides sufficient numbers for calculation of cumu-
lative incidences of cancer by organ, path_MMR variant and 
gender up to 75 years of age with reasonable precision. For some 
groups, we also present some figures for cumulative incidences 
up to 80 years of age.
In our two former reports1 2, we demonstrated differences in 
the penetrance and/or expression between pathogenic variants 
of the four MMR genes MLH1, MSH2, MSH6 and PMS2, and 
we demonstrated that within each group of path_MMR carriers, 
the annual incidences of cancers were age dependent. We also 
demonstrated that for carriers of pathogenic variants of a given 
MMR gene, annual incidence rates of cancers were similar in 
those who had a previous (early) cancer and those who did not. 
That is, cancers appeared to be age-dependent stochastic events 
and any putative differences in penetrance between carriers 
who had or did nor have an early cancer, including influences 
of inherited genetic modifiers and environmental factors could 
be ignored when compiling the current report based on the 
combined series of both sets of patients. We emphasise that while 
such factors may be important determinants of penetrance, it is 
nonetheless legitimate to combine the data from the previous 
reports and calculate results for the current report without them 
being subject to major confounders because of these factors.
This report together with the two former reports now provide 
information relevant to personalised medical care for patients 
with LS of any age, gender, with or without previous cancer and 
with any path_MMR variant.
MeThOds
recruitment and follow-up
PLSD database design and inclusion criteria have been described 
previously.1 2 This study is an open observational study without 
a control group. Path_MMR carriers aged 25 years or older 
on the day of their first prospectively planned and completed 
surveillance colonoscopy were included whether they had 
previous cancer. We have reported previously time to first 
cancer1 and time to any subsequent cancer2 up to 70 years in 
these patients. Any cancers that were diagnosed before or at 
the same age as the first prospectively planned and completed 
colonoscopy were scored as previous cancers, and all incident 
cancers reported here were detected at an older age than the 
age at inclusion. All patients received follow-up surveillance as 
reported previously (1-2, see onlineSupplementary table S1) 
until the last update of information when they were scored as 
alive or dead. All patients were followed up according to local 
clinical guidelines. Follow-up times were censored if a patient 
was lost to follow-up. Intervals between colonoscopies were 
not considered. Each patient was censored at the age at which 
the last information was available, which might have been a 
colonoscopy, any other clinical examination, a report from an 
examination done by others, or information that the patient 
had died, whichever came last. In this report, we consider only 
incidences and survival of cancers in patients with LS under-
going surveillance. As we found that cancers continued to occur, 
we are planning future studies to investigate the relationships 
significance of this study
What is already known on this subject?
 ► Inherited predisposition to colorectal, gynaecological, 
urinary tract, upper gastrointestinal and other cancers 
may be caused by pathogenic variants of mismatch repair 
(path_MMR) genes and is then commonly referred to as 
Lynch syndrome (LS).
 ► Most patients with LS undergoing surveillance nonetheless 
develop colorectal and/or other cancers but often survive 
both their first cancer and their subsequent cancers.
 ► Penetrance and expressions of the different path_MMR 
genes in older age are uncertain.
What are the new findings?
 ► Prostate, urinary tract, gastric, duodenal, bile duct and 
pancreatic cancers occurred frequently in older patients with 
LS.
 ► Prostate and urinary tract cancers predominantly occurred in 
path_MSH2 carriers.
 ► Upper gastrointestinal tract cancers predominantly occurred 
in path_MLH1 carriers.
 ► Ovarian cancer occurred predominantly in younger women, 
which is in contrast to ovarian cancers in path_BRCA1/2 
carriers and in the general population.
 ► Survival was very poor for bile duct and pancreatic cancers, 
intermediate for gastric, duodenal and urinary tract cancers 
and good for prostate cancer.
 ► Except for endometrial and prostate cancer, typical LS 
cancers were not diagnosed in path_PMS2 carriers.
how might it impact on clinical practice in the foreseeable 
future?
 ► Knowledge of path_MMR gene-specific incidence and 
survival of cancers affecting different organs will inform 
genetic counselling and clinical management in the ageing 
LS population.
 ► Risk assessment and surveillance in LS should be based on 
age, gender and the path_MMR gene involved.
 ► Subgroups of patients with LS defined by age and path_
MMR gene have high risks for different cancers, some with 
serious prognoses in older age.
 ► Prevention and cure of these late onset cancers is a growing 
clinical challenge in LS.
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between factors such as colonoscopy interval, adenoma detec-
tion and removal and the incidence and stage at diagnoses of 
colorectal cancer.
All patients were demonstrated to be carriers of path_MMR 
variants (as determined by reporting centres) by gene testing or 
were obligate carriers of familial path_MMR variants by pedi-
gree structure. All reported path_MMR variants were checked 
against the Leiden Open Variation Database (LOVD) for LS 
(http:// chromium. lovd. nl/ LOVD2/ colon_ cancer/) in October 
2015. Deletions in the EPCAM gene that silence MSH2 were 
scored as path_MSH2. In sum 1865 (59.7%) of the patients had 
pathogenic (class 5) variants, 42 (1.3%) patients had probably 
pathogenic (class 4) variants and the remaining 1212 (38.9%) 
patients had variants that were not found in LOVD.
The following information was used for analyses: gender, 
path_MMR variant, age at inclusion, age at last update, age at 
any cancer, cancers scored by the first three positions in the 
International Classification of Diseases version 9 (ICD9) diag-
nostic system and age at death. Cancer stage at diagnosis was 
not included.
Some centres have reported prospective findings inde-
pendently9–11 and their previously reported cases are included 
in the present series.
Statistical methods
The statistical methods were described in detail previously.1 
2 In short, annual incidence rates (AIRs) by age were calcu-
lated in 5-year cohorts from 25 to 75 years of age. Cumula-
tive incidence, denoted by Q, was computed starting at age 
25, assuming zero incidence before age 25, using the formula 
Q(age) = Q(age−1)+[1−Q(age−1)]·AIR(age) where AIR(age) 
is the annual incidence rate as estimated from the corresponding 
5-year interval. The 95% CIs were estimated as appropriate.
When calculating the AIR for a given cancer, only patients 
without previous cancer in that organ were included, and obser-
vation time was censored at first cancer in the organ, while 
cancers in other organs were ignored. This was considered 
appropriate based on our reported findings that LS patients with 
previous cancer have approximately the same incidence of subse-
quent cancers as those with no previous cancer.1 2 This way of 
calculating organ-specific cumulative incidences is in line with the 
established method for reporting cumulative incidence of breast 
and ovarian cancer separately in carriers of path_BRCA1/2.6 12
Lifetime cumulative incidence of cancer was calculated as cumu-
lative incidence from 25 to 75 years of age and compared with 
the population average from the reporting countries as extracted 
from http:// globocan. iarc. fr in December 2015. Specific lifetime 
cumulative incidences for duodenal, colon and rectal cancers 
were extracted from http:// www- dep. iarc. fr/ NORDCAN/ NO/ 
frame. asp in December 2015 for the year 2013. Relative cumu-
lative lifetime risk was calculated as observed cumulative life-
time incidence divided by population cumulative incidence at 75 
years. Crude 5-year and 10-year survival following cancer was 
assessed by the Kaplan-Meier survivor function for patients aged 
65 years or less at diagnoses.
ethics
All reporting centres exported only deidentified data to the joint 
database used for this report. All genetic tests were performed 
with appropriate informed consent according to local and 
national requirements for health care and/or research. No named 
data was exported from participating centres.
resulTs
A total of 3119 patients including 1723 females, and 1396 males 
met the inclusion criteria. The total number of observation years 
was 24 475. The numbers of patients and observation years were 
1473 and 13 846 for path_MLH1 carriers; 1060 and 7492 for 
path_MSH2 carriers; 462 and 2613 for path_MSH6 carriers; 
and 124 and 524 for path_PMS2 carriers. Mean age at inclusion 
by gene and gender varied from 41.5 to 53.3; carriers of path_
MSH6 and path_PMS2 were significantly older than carriers of 
path_MLH1 and path_MSH2 (table 1). Results for path_PMS2 
carriers are given, although numbers are generally insufficient to 
draw firm conclusions. In all, 813 cancers were diagnosed during 
follow-up. They affected 618 patients (20% of all patients with 
a mean of 1.3 cancers per affected patient) (details are given 
in online supplementary table S2). The observed incidences and 
cumulative incidences may be considered as risks of developing 
cancers and are discussed as such. Time from last ccolonosco-
pyto ccolorectalcancer in patients without prior cancer is given 
in our first report,1 and time from last colonoscopy to colorectal 
cancer in patients having had a prior cancer is given in our 
second report2
Cumulative incidences of cancer by organ and age
The cumulative incidences of cancers in individual organs or 
groups of organs from 25 years of age are shown in tables 2 and 
3. Cumulative incidence at 75 years for any cancer was 76% 
(95% CI 68.5% to 83.2%), 80% (95% CI 69.8% to 90.9%) and 
61% (95% CI 42.7% to 79.0%) for path_MLH1, path_MSH2 
and path_MSH6 carriers, respectively (table 2). A higher life-
time incidence for colorectal cancer was seen in path_MLH1 and 
path_MSH2 carriers compared with path_MSH6 carriers (46% 
(95% CI 37.8% to 53.9%), 43% (95% CI 33.2% to 52.8%) and 
15% (95% CI 3.3% to 26.6%), respectively). Colorectal cancer 
was not observed in the small number of path_PMS2 carriers 
studied. Most colorectal cancer affected the colon rather than 
the sigmoid or rectum (table 3). Lifetime incidences for endo-
metrial cancer were 43% (95% CI 33.1% to 52.3%); 57% (95% 
CI 41.8% to 71.6%) and 46% (95% CI 27.3% to 65.0%) for 
path_MLH1, path_MSH2 and path_MSH6 carriers, respectively. 
The corresponding incidences for ovarian cancer were: 10% 
(95% CI 4.8% to 15.4%), 17% (95% CI 5.7% to 28.0%) and 
13% (95% CI 0.1% to 31.2%), respectively. Most gynaecolog-
ical cancers occurred before the age of 60 years (tables 2 and 
3). There was a significantly higher incidence of colon cancer in 
middle-aged path_MLH1 males compared with females, but no 
significant gender differences were observed for colon cancer in 
path_MSH2 and path_MSH6 carriers (table 4).
Upper gastrointestinal cancers including those affecting the 
stomach, duodenum, bile duct, gall bladder or pancreas were 
diagnosed predominantly in old age. The cumulative lifetime 
incidence of upper gastrointestinal tumours was particularly 
high for path_MLH1 carriers (21% (95% CI 15.6% to 27.1%) 
compared with path_MHS2 carriers (10% (95% CI 4.1% to 
16.3%)) and path_MSH6 carriers (7% (95% CI 0% to 14.8%)) 
(table 2). Among upper gastrointestinal cancers, the cumula-
tive risk for stomach cancer was greatest: 7% (95% CI 3.5% 
to 10.8%) and 8% (95% CI 1.9% to 13.6%) for path_MLH1 
and path_MSH2 carriers, respectively. Urinary tract cancers 
also occurred predominantly in older age. Their incidence 
was elevated particularly in path_MSH2 carriers: 25% (95% 
CI 16.6% to 33.2%) compared with path_MLH1 carriers (8% 
(95% CI 4.3% to 11.7%)) and path_MSH6 carriers (11% 
(95% CI 1.7% to 20.3%)). Ureteric cancer was most prevalent. 
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Table 3 Cumulative incidences of individual cancers in carriers of path_MMR variants in the different genes from 25 years of age up to the age of 
75 are shown. Incidence of breast, endometrial and ovarian cancers were calculated in females and incidence of prostate cancers calculated in men; 
all others in both genders combined
ICd9 Organ Age
Cumulative incidence by age (% (95% CI))
path_MLH1 path_MSH2 path_MSH6 path_PMS2
Colorectal cancer
153 Colon 40 12.9 (8.8 to 17.1) 8.6 (3.9 to 13.3) 0 0
50 25.7 (20.7 to 30.7) 20.2 (13.9 to 26.4) 1.8 (0.0 to 5.2) 0
60 36.0 (30.4 to 41.6) 27.3 (20.3 to 34.3) 5.3 (0.0 to 11.2) 0
70 41.6 (35.2 to 48.0) 40.2 (31.3 to 49.1) 14.2 (3.1 to 25.4) 0
75 46.7 (39.2 to 54.3) 42.4 (32.9 to 51.9) 14.2 (3.1 to 25.4) 0
154 Sigmoid and rectum 40 1.6 (0.2 to 3.0) 0.6 (0.0 to 1.8) 0 0
50 3.2 (1.3 to 5.0) 4.7 (1.7 to 7.7) 0 0
60 6.3 (3.6 to 9.0) 9.8 (5.5 to 14.1) 3.0 (0.0 to 7.1) 0
70 9.2 (5.6 to 12.9) 13.5 (8.0 to 19.0) 4.6 (0.0 to 9.7) 0
75 11.8 (7.2 to 16.4) 18.3 (10.9 to 25.6) 4.6 (0.0 to 9.7) 0
Endometrial and ovarian cancer
182 Endometrium 40 3.1 (0.4 to 5.8) 1.5 (0.0 to 4.4) 0 0
50 18.7 (12.9 to 24.5) 15.9 (7.9 to 23.8) 15.4 (4.1 to 26.8) 0
60 34.8 (27.1 to 42.5) 40.9 (29.2 to 52.6) 33.2 (16.5 to 49.9) 26.4 (0.8 to 51.9)
70 40.3 (31.5 to 49.1) 52.7 (38.7 to 66.8) 46.2 (27.3 to 65.0) 26.4 (0.8 to 51.9)
75 42.7 (33.1 to 52.3) 56.7 (41.8 to 71.6) 46.2 (27.3 to 65.0) 26.4 (0.8 to 51.9)
183 Ovaries 40 2.6 (0.1 to 5.2) 3.8 (0.0 to 8.0) 4.2 (0.0 to 12.3) 0
50 6.8 (2.9 to 10.7) 10.7 (4.1 to 17.4) 4.2 (0.0 to 12.3) 0
60 8.6 (4.0 to 13.2) 12.3 (5.1 to 19.5) 4.2 (0.0 to 12.3) 0
70 10.1 (4.8 to 15.4) 16.9 (5.7 to 28.0) 13.1 (0.0 to 31.2) 0
75 10.1 (4.8 to 15.4) 16.9 (5.7 to 28.0) 13.1 (0.0 to 31.2) 0
Upper gastrointestinal cancer
151 Stomach 40 0.3 (0.0 to 0.9) 0 0 0
50 0.8 (0.0 to 1.7) 0.5 (0.0 to 1.4) 0 0
60 2.4 (0.7 to 4.0) 1.6 (0.0 to 3.4) 1.4 (0.0 to 4.2) 0
70 6.3 (3.0 to 9.7) 4.1 (0.8 to 7.5) 1.4 (0.0 to 4.2) 0
75 7.1 (3.5 to 10.8) 7.7 (1.9 to 13.6) 5.3 (0.0 to 13.1) 0
152 Duodenum 40 0.4 (0.0 to 1.1) 0 0 0
50 1.1 (0.0 to 2.3) 1.0 (0.0 to 2.3) 0 0
60 2.1 (0.5 to 3.7) 2.0 (0.1 to 4.0) 0 0
70 4.1 (1.4 to 6.8) 2.0 (0.1 to 4.0) 0 0
75 6.5 (2.7 to 10.2) 2.0 (0.1 to 4.0) 0 0
156 Bile duct and gall 
bladder
40 0 0 0 0
50 0.3 (0.0 to 0.8) 0 0 0
60 1.3 (0.0 to 2.5) 0 0 0
70 3.7 (1.3 to 6.2) 0 0 0
75 3.7 (1.3 to 6.2) 1.7 (0.0 to 5.1) 0 0
157 Pancreas 40 0.3 (0.0 to 0.9) 0 0 0
50 1.1 (0.0 to 2.1) 0 0 0
60 1.7 (0.3 to 3.1) 0.5 (0.0 to 1.5) 1.4 (0.0 to 4.2) 0
70 3.9 (1.4 to 6.4) 0.5 (0.0 to 1.5) 1.4 (0.0 to 4.2) 0
75 6.2 (2.6 to 9.8) 0.5 (0.0 to 1.5) 1.4 (0.0 to 4.2) 0
Urinary tract cancer
188 Urinary bladder 40 0 0 0 0
50 0.5 (0.0 to 1.2) 1.0 (0.0 to 2.3) 2.9 (0.0 to 7.0) 0
60 1.9 (0.4 to 3.4) 3.6 (1.0 to 6.3) 4.3 (0.0 to 9.1) 0
70 4.1 (1.5 to 6.7) 6.2 (2.3 to 10.2) 4.3 (0.0 to 9.1) 0
75 4.1 (1.5 to 6.7) 8.1 (2.8 to 13.3) 8.2 (0.0 to 16.9) 0
189 Ureter and kidney 40 0.3 (0.0 to 0.9) 0 0 0
50 0.8 (0.0 to 1.8) 2.4 (0.3 to 4.5) 0 0
60 1.1 (0.0 to 2.2) 6.9 (3.3 to 10.5) 1.4 (0.0 to 4.2) 0
70 3.8 (1.2 to 6.4) 16.0 (9.6 to 22.4) 3.0 (0.0 to 7.0) 0
Continued
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Cumulative incidences up to 75 years of age by path_MMR cate-
gory for any cancer, upper gastrointestinal cancer and urinary 
tract cancer are shown in figure 1.
The cumulative incidences at 75 years of age for prostate 
cancer were 17% (95% CI 8.5% to 25.3%), 32% (95% CI 11.7% 
to 51.5%) and 18% (95% CI 0% to 44.4%) for path_MLH1, 
path_MSH2 and path_MSH6 carriers, respectively. For detailed 
description of all observation years and incident cancer cases in 
each 5-year age group, see online supplementary table S3.
relative cumulative incidences
Cumulative incidences at 75 years of age were compared with 
population incidences to arrive at cumulative relative risk (RR) 
(see table 5). Path_MLH1, path_MSH2 and path_MSH6 carriers 
showed an RR of any cancer of 3.1 (95% CI 2.8 to 3.4), 3.3 
(95% CI 2.9 to 3.7) and 2.5 (95% CI 1.7 to 3.2), respectively. 
By genotype, path_MLH1 carriers had the highest RR for 
duodenal (RR 64.7), colon (RR 22.3), bile duct/gall bladder 
(RR 18.7) and pancreatic cancers (RR 7.8); path_MSH2 carriers 
had the highest RR for endometrial (RR 35.5), ovarian (RR 
16.9), urinary tract (RR 10.8) and prostate cancers (RR 3.2). 
Path_MSH6 carriers had similar RR for endometrial and ovarian 
cancer as path_MLH1 and path_MSH2 carriers (RR 28.8 and 
13.0, respectively) but less frequent cancer in other organs. The 
few path_PMS2 carriers included had endometrial prostate and 
breast cancers, but none of the other cancers typically seen in LS 
were diagnosed (table 5).
survival following cancer
Five-year and 10-year crude survival by affected organ for all 
cases diagnosed with cancer before 65 years of age are shown in 
table 6. Five-year survival was 96% for colon cancer and 75% 
for recto-sigmoid cancer. Corresponding 10-year survival was 
88% and 70%, respectively. Five-year survival for endometrial 
cancer was 93% and for ovarian cancer 83%, and corresponding 
10-year survival was 93% and 74%, respectively. Among other 
ICd9 Organ Age
Cumulative incidence by age (% (95% CI))
path_MLH1 path_MSH2 path_MSH6 path_PMS2
75 4.6 (1.6 to 7.6) 17.8 (10.6 to 25.0) 3.0 (0.0 to 7.0) 0
Other LS or possible LS cancers
174 Breast 40 0 2.6 (0.0 to 6.2) 0 0
50 2.9 (0.6 to 5.2) 5.2 (0.7 to 9.8) 0 0
60 8.3 (4.2 to 12.4) 6.1 (1.3 to 11.0) 4.7 (0.0 to 11.0) 8.6 (0.0 to 24.8)
70 12.0 (6.7 to 17.3) 11.5 (4.6 to 18.4) 13.3 (2.2 to 24.4) 8.6 (0.0 to 24.8)
75 12.0 (6.7 to 17.3) 11.5 (4.6 to 18.4) 13.3 (2.2 to 24.4) 55.9 (0.0 to 100.0)
185 Prostate 40 0 0 0 0 
50 0.6 (0.0 to 1.6) 0 0 37.9 (0.0 to 95.9)
60 5.3 (1.4 to 9.1) 4.2 (0.0 to 8.8) 0 37.9 (0.0 to 95.9)
70 13.3 (6.1 to 20.4) 13.2 (3.7 to 6.1) 4.4 (0.0 to 12.9) 37.9 (0.0 to 95.9)
75 16.9 (8.5 to 25.3) 31.6 (11.7 to 51.5) 18.3 (0.0 to 44.4) 37.9 (0.0 to 95.9)
191 Brain 40 0.3 (0.0 to 0.9) 0 0 0
50 0.3 (0.0 to 0.9) 0 0 0
60 0.3 (0.0 to 0.9) 1.1 (0.0 to 2.6) 1.4 (0.0 to 4.2) 0
70 1.0 (0.0 to 2.4) 1.9 (0.0 to 4.0) 1.4 (0.0 to 4.2) 0
75 1.0 (0.0 to 2.4) 5.3 (0.2 to 10.3) 1.4 (0.0 to 4.2) 0
LS, Lynch syndrome
Table 3 Continued 
Table 4 Cumulative incidence colon and sigmoidal-rectal cancer stratified by age, path_MMR variant and gender. There was no observed colon or 
sigmoid-rectal cancer in path_PMS2 carriers in any age group (see table 3)
Age
Cumulative incidence by age (% (95% CI))
path_MLH1 path_MSH2 path_MSH6
Females Males Females Males Females Males
Colon cancer 
(ICD9=153)
40 10.4 (5.2 to 15.6) 15.4 (9.0 to 21.9) 10.1 (2.9 to 17.3) 7.4 (1.2 to 13.6) 0 0
50 18.8 (12.6to 25.0) 33.3 (25.5 to 41.1) 23.8 (14.8 to 32.8) 15.8 (7.2 to 24.3) 0
60 28.1 (20.9 to 35.2) 45.2 (36.6 to 53.8)* 31.4 (21.9 to 41.0) 21.5 (11.3 to 31.6)
70 37.3 (28.5 to 46.1) 45.2 (36.6 to 53.8) 44.7 (33.7 to 55.7) 32.4 (17.7 to 47.2)
75 42.1 (31.8 to 52.5) 50.8 (40.1 to 61.5) 44.7 (33.7 to 55.7) 42.6 (20.4 to 64.9)
Sigmoid- rectal 
cancer(ICD9=154)
40 1.4 (0.0 to 3.3) 1.9 (0.0 to 4.1) 0 1.3 (0.0 to 3.8) 0 0
50 2.9 (0.3 to 5.4) 3.6 (0.8 to 6.4) 1.0 (0.0 to 3.0) 8.9 (3.0 to 14.7) 0 0
60 6.1 (2.4 to 9.8) 6.5 (2.6 to 10.5) 4.0 (0.2 to 7.8) 17.9 (9.2 to 26.5) 4.6 (0.0 to 10.7) 0
70 10.2 (4.9 to 15.6) 7.6 (3.2 to 12.1) 8.2 (2.2 to 14.3) 20.7 (10.7 to 30.7) 7.0to (0.0 to 14.6) 0
75 11.7 (5.7 to 17.7) 11.7 (4.7 to 18.7) 12.9 (4.4 to 21.3) 26.0 (12.3 to 39.7) 7.0 (0.0 to 14.6) 0
*Increased (p<0.05) compared with same-aged females.
**Lower (p<0.05) than in path_MLH1 or path_MSH2 carrier with same gender and age.
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extracolonic cancers, 5-year survival was also very good for 
prostate (100%), urine bladder (93%) and ureter and kidney 
(85%) cancers and remained good at 10 years. Five-year survival 
for stomach and duodenal cancer was lower at 61% and 67%, 
respectively, while 5-year survival was poor following bile duct 
or gallbladder cancer (29%) or pancreatic cancer (0%).
Given the high mortality of some late-onset cancers and the 
probability that individuals affected by early-onset cancers with 
good prognoses might have developed and died from such 
cancers later, we recalculated survival after censoring patients 
as lost to follow-up when they developed a cancer with <70% 
5-years survival. This did not result in any significant differ-
ences. The results of these calculations are illustrated in figure 2.
Combining risk for cancer and survival following cancer
Data on the risk of cancer affecting an organ and the chance of 
survival after that cancer occurs may be combined to calculate the 
risk of dying from a cancer in that organ. This combined risk may 
be calculated for a patient based on age, gender and path_MMR 
Figure 1 Cumulative incidences of colorectal cancer, upper gastrointestinal cancer (including stomach, duodenum, bile duct, gall bladder and 
pancreas) and urinary tract cancer (not including prostate).
Table 5 Relative cumulative incidence (RR) cancer at 75 years in carriers of path_MMR genes stratified by gene. 95% CIs are shown in 
parentheses. Significantly increased (p<0.05) RRs are highlighted in bold. Maximum RR by gene underlined
ICd9 Organ
Population 
incidence (%)
relative cumulative incidence (95% CI)
path_MLH1 path_MSH2 path_MSH6 path_PMS2
Any cancer 24.4 3.1 (2.8 to 3.4) 3.3 (2.9 to 3.7) 2.5 (1.7 to 3.2) 2.1 (0 to 4.1)
In separate organs order by RR
152 Duodenum 0.1 64.7 (27.4 to 102.1) 20.1 (0.6 to 39.6) 0 0
182 Endometrium 1.6 26.7 (20.7 to 32.7) 35.5 (26.1 to 44.8) 28.9 (17.1 to 40.6) 16.5 (0.5 to 32.4)
153 Colon 2.1 22.3 (18.7 to 25.9) 20.2 (15.6 to 24.7) 6.8 (1.5 to 12.1) 0
156 Bile duct and gall bladder 0.2 18.7 (6.3 to 31.1) 8.6 (0 to 25.4) 0 0
183 Ovary 1.0 10.1 (4.8 to 15.4) 16.9 (5.7 to 28.0) 13.1 (0 to 31.2) 0
189 Ureter and kidney 1.3 3.5 (1.2 to 5.9) 13.7 (8.2 to 19.2) 2.3 (0 to 5.4) 0
154 Sigmoid and rectum 1.4 8.4 (5.2 to 11.7) 13.0 (7.8 to 18.3) 3.3 (0 to 6.9) 0
191 Brain 0.5 1.9 (0 to 4.8) 10.5 (0.4 to 20.6) 2.9 (0 to 8.4) 0
151 Stomach 0.8 8.9 (4.4 to 13.4) 9.7 (2.3 to 17.0) 6.6 (0 to 16.4) 0
188 Urine bladder 1.0 4.1 (1.5 to 6.7) 8.1 (2.8 to 13.3) 8.2 (0 to 16.9) 0
157 Pancreas 0.8 7.8 (3.3 to 12.3) 0.6 (0 to 1.9) 1.8 (0 to 5.2) 0
185 Prostate 10 1.7 (0.9 to 2.7) 3.2 (1.2 to 5.1) 1.8 (0 to 4.4) 3.8 (0 to 9.6)
174 Breast 9.4 1.3 (0.7 to 1.8) 1.2 (0.5 to 2.0) 1.4 (0.2 to 2.6) 6.0 (0 to 10.6)
In anatomical regions ordered by RR
Gynaecological 2.6 19.1 (15.6 to 22.7) 25.3 (20.1 to 30.4) 20.8 (13.3 to 28.2) 10.1 (0.3 to 20)
Colorectal 3.8 12.1 (10 to 14.2) 11.3 (8.7 to 13.9) 3.9 (0.9 to 7.0) 0
Upper gastrointestinal cancer 1.9 11.2 (8.2 to 14.3) 5.4 (2.1 to 8.6) 3.5 (0 to 7.8) 0
Urinary tract cancer 2.3 3.5 (1.9 to 5.1) 10.8 (7.2 to 14.4) 4.8 (0.7 to 8.8) 0
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variant. As an example, the cumulative risk for colon cancer in 
a path_MSH6 carrier at 60 years is 5%, 10-year survival is 88% 
and the risk of developing and dying of colorectal cancer before 
70 years of age (subject to follow-up according to guidelines) 
is (5% · 12% =) 0.6%. Other examples may be: the combined 
risk for a path_MSH6 carrier of developing and dying from an 
ovarian cancer before 70 years would be (4% · 26% =) 1%. The 
combined risk for a path_MLH1 carrier of developing and dying 
from bile duct cancer before 80 years would be (4% · 86% =) 
3%. It follows from the CIs in tables 3 and 6 that such calculated 
Table 6 Five-year and 10-year overall survival calculated by the Kaplan-Meier algorithm stratified on diagnoses for patients prospectively 
diagnosed <65 years of age
ICd9 diagnosis Organ n
5-year survival 10-year survival
survival (%) 95% CI survival (%) 95% CI
Colorectal cancer
153 Colon 159 96 91% to 98% 88 77% to 94%
154 Sigmoid rectum 47 75 56% to 87% 70 49% to 84%
Gynaecological cancer
182 Endometrium 104 93 85% to 97% 93 85% to 97%
183 Ovary 25 83 55% to 94% 74 44% to 90%
Upper gastrointestinal tract cancer
151 Stomach 17 61 33% to 81% 61 33% to 81%
152 Duodenum 11 67 28% to 88% 67 28% to 88%
157 Pancreas 10 0
156 Bile duct and gall 
bladder
8 29 04% to 61% 14 1% to 47%
Urinary tract cancer
189 Ureter kidney 28 85 64% to 94% 71 34% to 89%
188 Urine bladder 20 93 59% to 99% 81 42% to 95%
Other
185 Prostate 17 100 80 20% to 97%
174 Breast 31 95 70% to 99% 89 61% to 97%
191 Brain 9 22 3% to 51% 22 3% to 59%
Figure 2 Kaplan-Meier estimates of 10-year crude survival following colon cancer, sigmoid-rectal cancer, endometrial cancer or ovarian cancer 
that was diagnosed before 65 years of age after censoring for upper gastrointestinal or brain tumours. Solid line indicates point values; dotted lines 
indicate 95% CIs.
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combined risks for contracting and dying from specific cancers 
have wide confidence intervals.
Path_MSH2 carriers had a substantial risk of urinary tract and 
prostate cancers in older ages and most but not all survived these 
cancers. In this report, the risk of cancer is presented for some 
ages only. Using our interactive website www. lscarisk. org, the 
risks of cancers may be calculated for patients with LS of any 
age.
dIsCussIOn
This study included both LS patients without a previous cancer 
and patients with LS who had survived early cancer(s), thereby 
providing numbers that were sufficient to calculate cancer risks 
stratified by path_MMR variant for each organ involved up to 75 
years of age. The majority of patients included in the study were 
path_MLH1 or path_MSH2 carriers, and the majority of older 
patients in these groups had survived previous cancer(s).1 2 The 
tables describing cumulative cancer incidences are the results of 
the study and are discussed below. An interactive website (www. 
lscarisk. org) based on online supplementary table S3 allows 
cancer risks to be calculated for any patients with LS simply 
by providing the patient’s age and gender and represents the 
applied outcome of the study.
Older path_MSH2 carriers had a particularly high incidence 
of urinary tract and prostate cancers, while older path_MLH1 
carriers had the highest incidence of upper gastrointestinal 
cancers. Survival was very poor for bile duct and pancreatic 
cancer, intermediate for gastric and urinary tract cancers and 
good for prostate cancer. These findings demonstrate that genetic 
subgroups in LS are at risk for different cancers in old age and 
that these cancers have very different prognoses. Compared with 
path_MLH1 and path_MSH2 carriers, we show that path_MSH6 
carriers are at lower risk for early onset cancer and, except for 
an intermediate risk for urinary tract or prostate cancer, at lower 
risk for late onset cancers too.
The current study refines estimates of cancer risk for all 
patients with LS but in particular provides data that will better 
inform counselling and clinical management of older patients 
with LS. Previous reports9–11 13–17 did not include sufficient 
numbers of patients to stratify cancer risk in older age by path_
MMR variant, as has been possible here.
Despite its international multicentre design, this study still 
identified too few path_PMS2 carriers to draw firm conclusions 
about their cancer risks. Apart from endometrial and prostate 
cancer, however, none of the cancers considered to be part of LS 
were diagnosed in path_PMS2 carriers.
We calculated the incidence of ovarian or endometrial cancer 
in female LS patients with censoring at prophylactic oophorec-
tomy or hysterectomy that was undertaken in some patients. In 
contrast to path_BRCA1/2 carriers12 and the general population, 
most ovarian cancers in LS were diagnosed before the meno-
pause, and their prognosis was good. This finding brings into 
question the practice of recommending prophylactic oophorec-
tomy at the menopause in females with LS.4
Risks for breast cancer in patients with LS were not increased 
significantly, and therefore we could not confirm previous 
reports that have suggested that breast cancer is part of the LS 
cancer spectrum17
The structure of the database (PLSD) established for our 
studies enables us to add any information of interest later for all 
patients. The results obtained so far raise further questions that 
we should now investigate, such as the relationships between 
colonoscopy interval, stage at prospectively detected CRC and 
its treatment and survival. We have a lot more to do, and we 
invite further centres to join PLSD so that we can answer these 
clinically important questions as quickly and as definitively as 
possible.
The novelty of this report is that we provide for the first 
time the empirical prospectively observed outcome of health-
care into old ages for patients with LS including stratification by 
path_MMR variant. Before management guidelines are revised 
to take account of this stratification, validation of the findings 
of this study should be achieved in at least one other similar 
but independent study. We are in collaboration with the Euro-
pean Hereditary Tumour Group (www. mallorca- group. org) and 
InSiGHT (www. insight- group. org) with the aim of establishing 
an independent series to validate the findings presented here. 
If our findings are confirmed, we may have a larger combined 
cohort to narrow the CIs of the observed point estimates before 
discussing conclusions with respect to clinical guidelines. To this 
end, we invite other centres with compatible cohorts of patients 
with LS to contribute. In particular, there is a need for much 
more data on path_PMS2 and path_MSH6 patients.
This is the first comprehensive study of cancer risk and prog-
nosis in older LS patients stratified by path_MMR variant. We 
have updated our website www. lscarisk. org to include the results 
presented here. Using the website, the age, gender and path_
MMR variant in any given patient may now be entered to calcu-
late the remaining lifetime risk for cancer in individual organs. 
This is likely to be of interest both to patients with LS and their 
healthcare providers
For further information on the collaborating activities, please 
visit http:// insight- group. org/ and http:// mallorca- group. org/.
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